drugset / Trial / NCT00325260

Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China

NCT00325260

Phase 3 Completed 900 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindPrevention

Summary

In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.

Timeline

Start
2006-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine

Indications

No indication recorded.